Serum microRNA-17 functions as a prognostic biomarker in osteosarcoma

Li, Shuai; Gao, Yong; Wang, Kun; Dai, Zhipeng; Xu, Dong; Liu, Wei; Li, Zhiliang; Zhang, Zhengdong; Yang, Shuai; Yang, Cao

doi:10.3892/ol.2016.5362

Cited by 20 publications

(17 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This demonstrated that certain miRNAs, including miR-33a, miR-150, miR-497 and miR-506, act as tumor suppressors ( 13 – 16 ). A number of previous studies have identified that miRNAs may serve as biomarkers for cancer risk stratification, outcome prediction, and even classification of the severity of the cancer ( 17 ). The identification of the miRNA molecule targets involved in tumor pathology may also provide insights into OS prognosis and facilitate the development of therapy for patients with OS ( 9 ).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‑124 acts as a tumor‑suppressive miRNA by inhibiting the expression of Snail2 in osteosarcoma

Huang

Liang

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

The aim of the present study was to investigate the clinical significance of hsa-microRNA-124-3p (miR-124) in osteosarcoma (OS), and examine its role in cell growth and invasion. Using a microRNA chip array, the expression of miR-124 was detected in samples of surgically resected OS and matched against the levels of expression in tumor-adjacent normal tissues. The levels of miR-124 were upregulated in the OS cells through the transfection of miR-124 mimics. Cell proliferation and Transwell assays were performed to determine cell proliferation and invasion; Reverse transcription-quantitative polymerase chain reaction, western blot and luciferase assays were then used to detect the expression of the target gene snail family zinc finger 2 (Snail2). The expression of miR-124 was significantly lower in the OS tissues, compared with that in the tumor-adjacent normal tissues; and the expression of miR-124 in the tumor tissues was significantly associated with tumor size. miR-124 directly repressed the expression of Snail2, and resulted in a significant inhibition of cell proliferation and invasion. In a mouse model, the overexpression of miR-124 significantly inhibited U2OS cell proliferation and invasion. Taken together, miR-124 was associated with the adverse clinical and pathological features observed in OS. It acted as a tumor suppressor to regulate the proliferation and invasion of OS cells by targeting Snail2, suggesting that miR-124 may be key in the progression of OS.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA‑124 acts as a tumor‑suppressive miRNA by inhibiting the expression of Snail2 in osteosarcoma

Huang

Liang

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…OS is the most common primary malignant bone tumor. Studies suggest that this tumor is associated with increased levels of circulating miRNAs (including 14q32 miRNAs, miR-95-3p, miR-300, miR-101, miR-542-3p, miR-196a, miR-196b, and miR-491) and with decreased levels of miR-17, miR-497, miR-106a-5p, miR-16-5p, miR-20a-5p, miR-425-5p, miR-451a, miR-25-3p, and miR-139-5p [26][27][28][29][30][31]47,51,52]. Of these, serum miR-199a-5p concentrations are significantly higher in OS patients than in controls, and are significantly lower in post-operative samples than in preoperative samples [53].…”

Section: Discussionmentioning

confidence: 99%

“…Extracellular miRNAs are highly stable and easily detected in various biofluids, including whole blood, plasma, and serum [25,47]. Although circulating miRNAs are considered to be non-invasive biomarkers for cancer diagnosis and prognosis, the association between circulating miRNA profiles and those in tumor tissues remains unclear [26,48]. Many studies conducted to date have yielded inconsistent results.…”

Section: Discussionmentioning

confidence: 99%

Signatures of circulating microRNA in four sarcoma subtypes

Koseła-Paterczyk¹,

Paziewska²,

Kulecka³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background: Sarcomas are rare malignant tumors of mesenchymal origin. The discovery of circulating biomarkers with high diagnostic value could supplement diagnosis of this heterogenous group of tumors. The aim of this study was to identify the profiles of circulating miRNA (c-miRNAs) in four groups of common bone and soft tissue sarcomas. Methods: At the time of diagnosis, blood samples were collected from 86 patients: 36 with locally advanced/unresectable/metastatic gastrointestinal stromal tumor (GIST) who received first-line treatment with imatinib; 16 with locally advanced osteosarcoma (OS); 26 with locally advanced synovial sarcoma (SS); and eight with locally advanced Ewing sarcoma (ES). In addition, samples were collected from 30 healthy controls. C-miRNAs were isolated using a miRCURY RNA Isolation Kit, followed by preparation of cDNA libraries and sequencing on the Ion Proton platform. Results: Pair-wise comparisons identified 156 unique c-miRNAs (adjusted P-value < 0.05) showing significant dysregulation between controls and patients; of these, 24, 36, 42, and 99 differentiated controls from pretherapeutic OS, SS, ES, and GIST, respectively. Ten c-miRNAs were commonly altered in at least three sarcoma types. Receiver operating characteristic curves and area under the curve (ROC-AUC) analyses revealed that a four-miRNA diagnostic classifier was able to differentiate controls from ES, GIST, OS, and SS, with AUC-ROC values of 1, 0.97, 0.95, and 0.94, respectively. Conclusions: Aberrant miRNA expression signatures were identified in serum from patients with four different sarcoma subtypes. Differences in miRNA expression profiles between sarcoma patients and healthy volunteers suggest that miRNAs may play a role in sarcoma development.

show abstract

“…Several other miRs, such as miR-21 and miR-17, are also expressed abnormally in the serum of patients with osteosarcoma. 30 , 31 Genome-wide microarray analysis might be an ideal way to identify circulating miRs with diagnostic ability, and a blood-based biomarker panel including more miRs and other molecular markers would help to improve the sensitivity and specificity.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

ObjectiveThis study was performed to examine serum microRNA-375 (miR-375) expression in patients with osteosarcoma and determine its diagnostic and prognostic value.MethodsSerum samples were obtained from 95 patients with osteosarcoma and 95 healthy individuals. miR-375 expression was detected by real-time polymerase chain reaction. The associations of serum miR-375 expression with the patients’ clinicopathological characteristics and prognosis were then evaluated. Receiver operating characteristic curve analysis was performed to obtain the potential value of serum miR-375 as a biomarker for osteosarcoma diagnosis and chemosensitivity prediction.ResultsSerum miR-375 expression was significantly lower in patients with osteosarcoma than in healthy individuals. Low serum miR-375 levels were associated with advanced clinical stages, large tumor size, positive distant metastasis, and poor tumor response to preoperative chemotherapy. Receiver operating characteristic curve analysis illustrated that serum miR-375 could distinguish patients with osteosarcoma from healthy individuals and distinguish patients with a good pathologic response from those with a poor response. Multivariate analysis confirmed low serum miR-375 expression as a statistically significant independent unfavorable prognostic factor.ConclusionsSerum miR-375 expression was downregulated in patients with osteosarcoma and might serve as a biomarker for its diagnosis, prognosis, and chemosensitivity prediction.

show abstract

Serum microRNA-17 functions as a prognostic biomarker in osteosarcoma

Cited by 20 publications

References 38 publications

MicroRNA‑124 acts as a tumor‑suppressive miRNA by inhibiting the expression of Snail2 in osteosarcoma

MicroRNA‑124 acts as a tumor‑suppressive miRNA by inhibiting the expression of Snail2 in osteosarcoma

Signatures of circulating microRNA in four sarcoma subtypes

MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma

Contact Info

Product

Resources

About